In summary, the studies presented above highlight the ability of GCGR activation to raise metabolic rate in both fed and fasted conditions, and further validate the glucagon-GCGR axis as an attractive therapeutic mechanism to pair with obesity medications that reduce body weight by suppressing caloric intake. The gene discussed is GCGR; the disease is obesity disorder.